IMS 2023 | Clinical trials exploring treatment approaches for high-risk NDMM
Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses current trials that are evaluating treatment approaches for high-risk newly diagnosed multiple myeloma (HR-NDMM), including the GMMG-CONCEPT trial (NCT03104842) and the OPTIMUM/MUK Nine b trial (NCT03188172). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory role/honoraria: GSK, Sanofi, Janssen, Bristol Myers Squibb/Celgene
Research support: AbbVie, GSK (both to the institution)
Travel support: Sanofi
Other (travel support, training): GSK, Sanofi, AbbVie
